Overview
Indications
® 2 ZAFEMYis indicated for the prevention of pregnancy in women with a body mass index (BMI) < 30 kg/mfor whom a combined hormonal contraceptive is appropriate. Limitations of Use: 2 Contraindications (4) Warnings and Precautions (5.1) Clinical Studies (14) [see,and]. ZAFEMY may be less effective in preventing pregnancy in women who weigh 198 lbs (90 kg) or more. ZAFEMY is contraindicated for use in women with BMI ≥ 30 kg/m
Boxed Warning
FDA Black Box Warning
ZAFEMY 2 is contraindicated in women with a BMI ≥ 30 kg/m. The risk of VTE may be greater with ZAFEMY 2 in women with a BMI > 30 kg/mcompared to women with a lower BMI Contraindications (4) [see Warnings and Precautions (5.1) ] and . Cigarette Smoking and Serious Cardiovascular Events Cigarette smo
Contraindications
When this intervention should not be used
ZAFEMY is contraindicated in females who are known to have or develop the following conditions: At high risk of arterial or venous thromboembolic events. Examples include women who: Boxed Warning [see, Warnings and Precautions (5.1) ] Smoke, if over age 35and Warnings and Precautions (5.1) [see] Hav
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Norelgestromin (substance)
- SNOMED CT
- 385578004
- UMLS CUI
- C1120952
- RxNorm CUI
- 326374
- Labeler
- AvKARE
Clinical Data
This intervention maps to 0 entities in the Ltrl knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.